BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34302528)

  • 1. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression.
    Gundlach JP; Hauser C; Schlegel FM; Willms A; Halske C; Röder C; Krüger S; Röcken C; Becker T; Kalthoff H; Trauzold A
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3313-3324. PubMed ID: 34302528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
    Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
    BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma.
    Hristov AC; Cope L; Reyes MD; Singh M; Iacobuzio-Donahue C; Maitra A; Resar LM
    Mod Pathol; 2009 Jan; 22(1):43-9. PubMed ID: 18843278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma.
    Piscuoglio S; Zlobec I; Pallante P; Sepe R; Esposito F; Zimmermann A; Diamantis I; Terracciano L; Fusco A; Karamitopoulou E
    Histopathology; 2012 Feb; 60(3):397-404. PubMed ID: 22276603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue.
    Abe N; Watanabe T; Suzuki Y; Matsumoto N; Masaki T; Mori T; Sugiyama M; Chiappetta G; Fusco A; Atomi Y
    Br J Cancer; 2003 Dec; 89(11):2104-9. PubMed ID: 14647145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-497 inhibits cell proliferation and invasion ability by targeting HMGA2 in pancreatic ductal adenocarcinoma.
    Zhou ZG; Xu C; Dong Z; Wang YP; Duan JY; Yan CQ
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):122-129. PubMed ID: 31957824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.
    Strell C; Norberg KJ; Mezheyeuski A; Schnittert J; Kuninty PR; Moro CF; Paulsson J; Schultz NA; Calatayud D; Löhr JM; Frings O; Verbeke CS; Heuchel RL; Prakash J; Johansen JS; Östman A
    Br J Cancer; 2017 Jun; 117(1):65-77. PubMed ID: 28524160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
    Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM
    Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.
    Liu Z; Wu K; Yang Z; Wu A
    Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.
    Li K; Yang J; Chen J; Shi Y; Zhang Z; Chen W
    Oncol Lett; 2020 Feb; 19(2):1584-1592. PubMed ID: 31966084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
    Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
    Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2.
    Wang YD; Mao JD; Wang JF; Xu MQ
    Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
    Paladino D; Yue P; Furuya H; Acoba J; Rosser CJ; Turkson J
    Oncotarget; 2016 Feb; 7(6):7253-67. PubMed ID: 26695438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of subcellular localization of TEAD transcription factors with outcome and progression in pancreatic ductal adenocarcinoma.
    Drexler R; Fahy R; Küchler M; Wagner KC; Reese T; Ehmke M; Feyerabend B; Kleine M; Oldhafer KJ
    Pancreatology; 2021 Jan; 21(1):170-179. PubMed ID: 33317954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
    Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
    Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma.
    Sperveslage J; Frank S; Heneweer C; Egberts J; Schniewind B; Buchholz M; Bergmann F; Giese N; Munding J; Hahn SA; Kalthoff H; Klöppel G; Sipos B
    Int J Cancer; 2012 Aug; 131(4):E371-81. PubMed ID: 22020953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.